Watch Out Viagra! UK’s Futura Set To Shake Up Global ED Market With MED3000
Executive Summary
HBW Insight talks exclusively to Futura Medical about its new erectile dysfunction product MED3000, which it says could take the global OTC market by storm.
You may also be interested in...
Futura All Set For US FDA De Novo Application For Eroxon OTC ED Treatment
Futura Medical is preparing to seek approval from the FDA to launch OTC in the US its MED3000 erectile dysfunction treatment, marketed in Europe under the Eroxon brand name. After completing all the necessary studies demonstrating that the gel-based, drug-free product works as a self-care treatment for ED, Futura says it is confident that the soon to be submitted de novo medical device application will be successful and pave the way for a Q1 2023 launch.
Futura Pens Deal With Cooper To Launch Erectile Dysfunction Gel In Europe
Futura Medical's novel OTC topical erectile dysfunction treatment MED3000 will be launched across numerous European markets by France's Cooper Consumer Health.
Futura Gains EU CE Mark For Drug-Free OTC Erectile Dysfunction Treatment
Futura Medical has received a CE Mark for its MED3000 erectile dysfunction treatment, which combines in gel form a mixture of volatile and non-volatile ingredients.